Solara's strong Q4 lifts FY26 finish but ibuprofen drag forces strategic review
The Ibuprofen business posted a negative EBITDA of Rs. 179 million in Q4 despite revenue rising 61% year-on-year to Rs. 849 million
The Ibuprofen business posted a negative EBITDA of Rs. 179 million in Q4 despite revenue rising 61% year-on-year to Rs. 849 million
The initiative by Rheumatology Association of Gujarat is aimed at strengthening patient-centric autoimmune care
The move signals a strategic pivot toward deeper integration between clinical leadership and medical technology developers
Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada
The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market
The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026
The state has received Rs. 84,000 crore investments in the sector over two years, positioning Hyderabad among the world’s leading life sciences clusters
The target reach is of more than 30 million young people and caregivers across 21 countries
The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents
Subscribe To Our Newsletter & Stay Updated